Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Qualigen Therapeutics, Inc. (not Aixcrypto Holdings, Inc.) on October 25, 2024. The filing details the voting results for six proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders approved all six proposals presented at the Annual Meeting:
- Director Elections: All five nominees (Robert Lim, Campbell Becher, Cody Price, Kevin A. Richardson, II, and Braeden Lichti) were elected. Each received over 14.3 million votes "For" with zero votes "Against."
- Independent Auditor: The appointment of WithumSmith+Brown, PC was ratified with approximately 17.0 million votes "For" versus 546,005 "Against."
- Reverse Stock Split: Stockholders approved an amendment to the certificate of incorporation to effect a reverse stock split with a ratio ranging from 10:1 to 50:1. The proposal received 16.1 million votes "For" and 1.4 million "Against."
- Adjournment: The proposal to adjourn the meeting if necessary to solicit additional proxies was approved.
- Alpha Capital Issuance: Stockholders approved the issuance of more than 20% of outstanding common stock to Alpha Capital Anstalt ("Alpha") to comply with Nasdaq Listing Rule 5635(d). This relates to an 8% Senior Convertible Debenture and a common stock purchase warrant. The proposal received 14.5 million votes "For" and 347,563 "Against."
- Executive Compensation: The advisory proposal to approve named executive officer compensation was approved with 14.5 million votes "For" and 297,422 "Against."
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the context of the approved reverse stock split and the significant equity issuance to Alpha Capital Anstalt. The approval of the reverse stock split suggests the company is taking measures to maintain compliance with Nasdaq listing standards.
Investor Verification Checklist
- Verify the exact reverse stock split ratio (between 10:1 and 50:1) to be determined by the Board of Directors.
- Review the terms of the 8% Senior Convertible Debenture and the warrant issued to Alpha Capital Anstalt to understand the dilution impact.
- Confirm the effective date of the reverse stock split and the impact on share price and trading volume.
- Check subsequent filings for the appointment of a permanent CEO, as the report was signed by an Interim CEO.